Lasers vs. Stents: Comparing SLT and MicroPulse Therapy for Early-Stage Glaucoma
Managing early-stage glaucoma in Australia has undergone a paradigm shift. For decades, daily eye drops were the first line of defense. Today, clinical data and Medicare-supported pathways favor early intervention with advanced laser technologies and minimally invasive surgical options.
When evaluating Lasers vs. Stents: Comparing SLT and MicroPulse Therapy for Early-Stage Glaucoma, patients and clinicians must weigh the efficacy of Selective Laser Trabeculoplasty (SLT) against the newer MicroPulse TLT, while considering where traditional “stents” (MIGS) fit into the treatment algorithm.
This guide provides a deep dive into these technologies to help you understand the best path for maintaining long-term ocular health and intraocular pressure (IOP) stability.
See more: Patient Experiences: Real Stories from People Who Had Laser Eye Surgery
Understanding Early-Stage Glaucoma Treatment in Australia
Glaucoma is often called the “silent thief of sight.” In its early stages, the primary goal is to lower intraocular pressure to prevent damage to the optic nerve. In the Australian healthcare landscape, the LiGHT trial has significantly influenced how we approach this, positioning laser therapy as a preferred primary treatment over lifelong medication.
What is SLT (Selective Laser Trabeculoplasty)?
SLT is a cold laser therapy used to treat open-angle glaucoma. It targets specific pigmented cells in the trabecular meshwork (the eye’s drainage system) without causing thermal damage to surrounding tissue.
What is MicroPulse Therapy?
MicroPulse Transscleral Laser Therapy (TLT) uses a “flickering” laser beam. By delivering energy in short bursts followed by rest periods, it lowers IOP by stimulating the drainage pathways and reducing fluid production without the tissue coagulation seen in older laser styles.
What are Glaucoma Stents (MIGS)?
Micro-Invasive Glaucoma Surgery (MIGS) involves the implantation of tiny devices, like the iStent or Hydrus, usually during cataract surgery. These stents create a permanent bypass through the eye’s natural drainage blockage.
Lasers vs. Stents: Comparing SLT and MicroPulse Therapy for Early-Stage Glaucoma
Choosing between these options depends on the specific anatomy of the patient’s eye and the severity of the pressure elevation.
1. Selective Laser Trabeculoplasty (SLT)
SLT remains the “gold standard” for initial laser intervention. It is a non-invasive, out-patient procedure that takes roughly five minutes per eye.
- Mechanism: It triggers a biological remodeling of the drainage tissue, allowing fluid to exit more freely.
- Suitability: Ideal for newly diagnosed patients or those who struggle with eye drop compliance.
- Success Rate: Approximately 75% to 80% of patients see a significant reduction in IOP.
2. MicroPulse Laser Therapy
While SLT targets the “drain,” MicroPulse is often more versatile. It can be used across various stages of glaucoma, not just the earliest onset.
- Mechanism: It utilizes a “micro-pulsing” delivery to minimize heat buildup, making it repeatable and safer for sensitive tissues.
- Suitability: Often used when SLT hasn’t provided sufficient results or for patients with slightly more advanced early-stage symptoms.
3. Glaucoma Stents (MIGS)
Stents are physical implants. While lasers modify the existing tissue, stents provide a brand-new “pipe” for the fluid.
- Mechanism: Bypasses the resistance in the trabecular meshwork.
- Suitability: Most commonly performed in Australia in conjunction with cataract surgery.
| Feature | SLT Laser | MicroPulse Laser | MIGS (Stents) |
| Invasiveness | Non-invasive | Non-invasive | Minimally Invasive |
| Procedure Time | 5–10 Minutes | 10–15 Minutes | 15–30 Minutes |
| Recovery | Immediate | 24–48 hours | 1–2 weeks |
| Repeatable? | Yes | Yes | No (Permanent) |
Benefits and Clinical Outcomes
When comparing these treatments, the “best” choice is the one that achieves the target pressure with the fewest side effects.
Benefits of Laser (SLT/MicroPulse)
- No Surgery Required: No incisions or risk of endophthalmitis (internal infection).
- Cost-Effective: Covered under Medicare with minimal out-of-pocket costs compared to surgical hardware.
- Drop Independence: Many patients can stop using daily eye drops, avoiding redness and irritation.
Benefits of Stents
- Constant Filtration: Unlike lasers, which may wear off after 3–5 years, a stent is a permanent mechanical solution.
- Combined Procedure: Efficiently treats both cataracts and glaucoma in a single sitting.
The Step-by-Step Treatment Framework
In Australian ophthalmic practice, the typical journey for a patient diagnosed with early-stage glaucoma follows this logical progression:
- Comprehensive Diagnostics: OCT scanning of the nerve fiber layer and visual field testing.
- The “Laser-First” Discussion: Evaluating SLT as a way to avoid the side effects of medications.
- Procedure Execution: The laser is performed in a clinic setting using a specialized lens.
- Post-Operative Review: Pressure check at 1 week and 4 weeks to determine efficacy.
- Long-Term Monitoring: Bi-annual check-ups to ensure the laser effect remains stable.
Common Mistakes and Best Practices
Mistake: Waiting Too Long for Intervention
Many patients wait until their vision changes to seek treatment. Because glaucoma vision loss is permanent, “early-stage” is the most critical time to utilize SLT or MicroPulse.
Best Practice: Personalized Target Pressure
Ensure your ophthalmologist sets a specific “Target IOP.” If SLT gets you to 18 mmHg but your target is 15 mmHg, a MicroPulse or Stent might be the necessary secondary step.
Mistake: Ignoring Dry Eye Symptoms
Traditional glaucoma drops often contain preservatives that cause dry eye. Opting for Lasers vs. Stents early on can preserve the health of the ocular surface.
Internal & External Authority References
Internal Linking Opportunities (Anchor Text Only):
- comprehensive eye examination Melbourne
- managing glaucoma symptoms
- minimally invasive glaucoma surgery benefits
- understanding intraocular pressure
Authoritative External References:
- Glaucoma Australia (Patient Support and Research)
- The Royal Australian and New Zealand College of Ophthalmologists (RANZCO)
FAQ: Frequently Asked Questions
Is SLT laser painful?
Most patients describe the sensation as a slight tapping or a small “pinprick.” It is performed using numbing drops, so there is no sharp pain.
How long do glaucoma stents last?
Stents like the iStent are designed to be permanent. They are made of medical-grade titanium and generally do not need to be replaced.
Can I have MicroPulse if SLT failed?
Yes. MicroPulse uses a different wavelength and delivery method, making it a viable “second-step” laser treatment if SLT did not achieve the desired pressure drop.
What is the recovery time for laser therapy?
Most patients can return to work and normal activities the very next day. You may experience slight blurring for a few hours immediately following the procedure.
Is laser treatment covered by Medicare in Australia?
Yes, SLT and certain MicroPulse procedures have specific Medicare Benefit Schedule (MBS) items, making them accessible to most Australians.
Conclusion: Taking the Next Step
The debate of Lasers vs. Stents: Comparing SLT and MicroPulse Therapy for Early-Stage Glaucoma ultimately comes down to your unique clinical profile. SLT offers a non-invasive, highly effective starting point, while MicroPulse and Stents provide powerful alternatives for those requiring more significant pressure management.